Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis

Xu, Ping; Chen, Hui; Xu, Jing; Wu, MF; Zhu, Xiulin; Wang, Fengping; Chen, Sufang; Xu, Junhua

doi:10.1016/j.ijid.2017.05.003

Cited by 18 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall data showed that the introduction of moxifloxacin in the early treatment regimen could significantly increase the bacteriostasis of the treatment regimen. Furthermore, the previous metaanalysis of Xu et al involved only three studies that reported results related to the recurrence rate (27), and found that moxifloxacin could significantly reduce the recurrence rate.…”

Section: Discussionmentioning

confidence: 99%

Moxifloxacin is a safe and effective candidate agent for tuberculosis treatment: a meta-analysis of randomized controlled trials

Sun¹,

Fan²

2021

Ann Palliat Med

View full text Add to dashboard Cite

Background: Moxifloxacin is a fourth-generation fluoroquinolone that has shown good antibacterial activity against both gram-positive cocci and gram-negative bacteria. The purpose of this study was to evaluate the safety and efficacy of moxifloxacin in the drug treatment regimen of patients with tuberculosis. Methods:We conducted an electronic database search of the PubMed, Embase, the Cochrane Controlled Center Register of Controlled Trials (CENTRAL), Web of Science, Baidu Scholar, and Google Scholar for literature related to clinical randomized controlled trials (RCTs) of tuberculosis patients (from the date of inception of the database to September 25, 2020). The experimental group received moxifloxacin while the control group did not use moxifloxacin. After literature screening, data extraction, and literature quality evaluation, the included studies were meta-analyzed using RevMan software 5.1.Results: In total, 13 RCTs involving 7,774 patients were included in this meta-analysis. The negative rate of sputum culture in the experimental group (which received moxifloxacin) was significantly higher than that of the control group after 2 months of treatment [relative risk (RR) =1.12, 95% confidence interval (CI):1.06-1.18, P<0.0001]. Treatment-related complications in the experimental group were significantly greater than those in the control group (RR =1.34, 95% CI: 1.07-1.67, P=0.01). There was no significant difference in the incidence of serious complications between the two groups (RR =1.09, 95% CI: 0.90-1.33, P=0.38). In addition, there were no significant differences in mortality and recurrence rate between the two groups (RR

show abstract

Section: Discussionmentioning

confidence: 99%

Moxifloxacin is a safe and effective candidate agent for tuberculosis treatment: a meta-analysis of randomized controlled trials

Sun¹,

Fan²

2021

Ann Palliat Med

View full text Add to dashboard Cite

show abstract

“…Caution is required with patients having an increased risk for tachyarrhythmia because it induces QT interval prolongation [ 31 ]. However, a meta-analysis done to determine its effectiveness and safety for tuberculosis treatment concluded that the combination of moxifloxacin with the recommended regimen for the treatment of TB, with a daily dose of 400 mg given for at least 2 months, does not cause additional adverse events [ 32 ].…”

Section: Main Textmentioning

confidence: 99%

An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP++

et al. 2018

View full text Add to dashboard Cite

The ongoing transmission of Mycobacterium (M.) leprae reflected in a very slow decline in leprosy incidence, forces us to be innovative and conduct cutting-edge research. Single dose rifampicin (SDR) as post-exposure prophylaxis (PEP) for contacts of leprosy patients, reduces their risk to develop leprosy by 60%. This is a promising new preventive measure that can be integrated into routine leprosy control programmes, as is being demonstrated in the Leprosy Post-Exposure Programme that is currently ongoing in eight countries.The limited (60%) effectiveness of SDR is likely due to the fact that some contacts have a preclinical infection beyond the early stages for which SDR is not sufficient to prevent the development of clinical signs and symptoms of leprosy. An enhanced regimen, more potent against a higher load of leprosy bacteria, would increase the effectiveness of this preventive measure significantly.The Netherlands Leprosy Relief (NLR) is developing a multi-country study aiming to show that breaking the chain of transmission of M. leprae is possible, evidenced by a dramatic reduction in incidence. In this study the assessment of the effectiveness of an enhanced prophylactic regimen for leprosy is an important component. To define the so called PEP++ regimen for this intervention study, NLR convened an Expert Meeting that was attended by clinical leprologists, public health experts, pharmacologists, dermatologists and microbiologists.The Expert Meeting advised on combinations of available drugs, with known efficacy against leprosy, as well as on the duration of the intake, aiming at a risk reduction of 80–90%. To come to a conclusion the Expert Meeting considered the bactericidal, sterilising and bacteriostatic activity of the potential drugs. The criteria used to determine an optimal enhanced regimen were: effectiveness, safety, acceptability, availability, affordability, feasibility and not inducing drug resistance.The Expert Meeting concluded that the enhanced regimen for the PEP++ study should comprise three standard doses of rifampicin 600 mg (weight adjusted when given to children) plus moxifloxacin 400 mg given at four-weekly intervals. For children and for adults with contraindications for moxifloxacin, moxifloxacin should be replaced by clarithromycin 300 mg (weight adjusted).

show abstract

“…[7] Moreover, Quinolines have been found to process several bioactivities including anti-malarial, antimicrobial, antioxidant, anti-tubercular, anti-asthmatic, anti-inflammatory, antihypertensive, and antiviral activities, [8] In addition, it shows some of the unique activities including antiplasmodial, [9] Immune depressing, [10] show binding affinities in estrogen receptor β, and functions in the mammalian reproductive system. [11] Among them, few of the promising drug molecules with Quinoline ring system, similar to Chloroquine, [12] Mefloquine, [13] Primaquine, [14] Ciprofloxacin, [15] Moxifloxacin, [16] Gatifloxacin, [17] Quinine, [18] Quinidine, [19] and Clioquinol. [20] (Figure 1) For the construction of this noble molecule, there are enormous synthetic methods that have been reported, including classical methods like Skraup, [21] Friedlander, Doebner-von-Miller, [22] Conrad-Limpach, Pfitzinger reaction [23] and so forth.…”

Section: Introductionmentioning

confidence: 99%

Radical Transformations towards the Synthesis of Quinoline: A Review

Teja

Khan

2020

Chemistry An Asian Journal

View full text Add to dashboard Cite

Quinoline is considered one of the most ubiquitous heterocycles due to its engaging biological activities and synthetic utility over organic transformations. Over the past few decades, numerous reports have been documented in the synthesis of quinolines. The classical methods including, Skraup, Friedlander, Doebner‐von‐Miller, Conrad‐Limpach, Pfitzinger quinoline synthesis, and so forth, these are the well‐known methods to construct principal quinoline scaffold with several advantages and limitations. Recently, radical insertion or catalyzed reactions have emerged as a powerful and efficient tool to construct heterocycles with high atom efficiency and step economy. In this concern, this minireview mainly focused on the developments of Quinoline synthesis via radical reactions. In addition, a brief description of the preparation procedure, reactivity, and mechanisms is also included, where as possible. Respectively, the synthesis of quinolines is classified and summarized based on its reactivity, so it will help the researchers to grab the information in this exploration area, as Quinolines are promising pharmacophores.

show abstract

Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis

Abstract: This meta-analysis suggests that the introduction of moxifloxacin into the recommended regimen for the treatment of non-drug resistant TB improves the clinical outcome by elevating the culture conversion rate and reducing the recurrence rate.

Cited by 18 publications

References 22 publications

Moxifloxacin is a safe and effective candidate agent for tuberculosis treatment: a meta-analysis of randomized controlled trials

Moxifloxacin is a safe and effective candidate agent for tuberculosis treatment: a meta-analysis of randomized controlled trials

An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP++

Radical Transformations towards the Synthesis of Quinoline: A Review

Contact Info

Product

Resources

About